WASHINGTON — Congress’ efforts to get more information on the business practices of pharmacy benefit managers are running into an unlikely roadblock: Republicans’ dislike of Federal Trade Commission Chair Lina Khan and her approach to antitrust enforcement.
The Senate Commerce Committee held a hearing Thursday on a bipartisan bill that aims to get the drug middlemen to tell the FTC how much money they make through pharmacy fees and “spread pricing,” a practice of charging insurers more for drugs than the PBMs pay pharmacies, and pocketing the difference.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
